6ZCZ

Crystal structure of receptor binding domain of SARS-CoV-2 Spike glycoprotein in ternary complex with EY6A Fab and a nanobody.

6ZCZ の概要

• エントリーDOI: 10.2210/pdb6zcz/pdb
• 分子名称: Spike protein S1, Nanobody, EY6A heavy chain, ... (7 entities in total)
• 機能のキーワード: ey6a, rbd, spike glycoprotein, sars-cov-2, human neutralizing antibody, viral protein, immune system
• 由来する生物種: Severe acute respiratory syndrome coronavirus 2; 詳細
• タンパク質・核酸の鎖数: 4
• 化学式量合計: 87950.27

構造登録者

Zhou, D.,Zhao, Y.,Fry, E.E.,Ren, J.,Stuart, D.I. (登録日: 2020-06-12, 公開日: 2020-06-24, 最終更新日: 2024-01-24)

主引用文献

Zhou, D.,Duyvesteyn, H.M.E.,Chen, C.P.,Huang, C.G.,Chen, T.H.,Shih, S.R.,Lin, Y.C.,Cheng, C.Y.,Cheng, S.H.,Huang, Y.C.,Lin, T.Y.,Ma, C.,Huo, J.,Carrique, L.,Malinauskas, T.,Ruza, R.R.,Shah, P.N.M.,Tan, T.K.,Rijal, P.,Donat, R.F.,Godwin, K.,Buttigieg, K.R.,Tree, J.A.,Radecke, J.,Paterson, N.G.,Supasa, P.,Mongkolsapaya, J.,Screaton, G.R.,Carroll, M.W.,Gilbert-Jaramillo, J.,Knight, M.L.,James, W.,Owens, R.J.,Naismith, J.H.,Townsend, A.R.,Fry, E.E.,Zhao, Y.,Ren, J.,Stuart, D.I.,Huang, K.A.
Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient.
Nat.Struct.Mol.Biol., 27:950-958, 2020

PubMed Abstract: The COVID-19 pandemic has had an unprecedented health and economic impact and there are currently no approved therapies. We have isolated an antibody, EY6A, from an individual convalescing from COVID-19 and have shown that it neutralizes SARS-CoV-2 and cross-reacts with SARS-CoV-1. EY6A Fab binds the receptor binding domain (RBD) of the viral spike glycoprotein tightly (K of 2 nM), and a 2.6-Å-resolution crystal structure of an RBD-EY6A Fab complex identifies the highly conserved epitope, away from the ACE2 receptor binding site. Residues within this footprint are key to stabilizing the pre-fusion spike. Cryo-EM analyses of the pre-fusion spike incubated with EY6A Fab reveal a complex of the intact spike trimer with three Fabs bound and two further multimeric forms comprising the destabilized spike attached to Fab. EY6A binds what is probably a major neutralizing epitope, making it a candidate therapeutic for COVID-19.

PubMed: 32737466
DOI: 10.1038/s41594-020-0480-y

実験手法

X-RAY DIFFRACTION (2.65 Å)